Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 65,585 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired 65,585 shares in Supernus Pharmaceuticals, valued at approximately $2,148,000, representing about 0.12% ownership of the company.
• Other major investors have significantly increased their stakes, with Woodline Partners LP boosting its position by 124.8% and BNP Paribas Financial Markets by 248.0% during the last quarter.
• Analysts have mixed opinions on Supernus Pharmaceuticals, with Cantor Fitzgerald upgrading the stock to "overweight" with a price target of $42, while Wall Street Zen downgraded it from "buy" to "hold."

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 65,585 shares of the specialty pharmaceutical company's stock, valued at approximately $2,148,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.12% of Supernus Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vident Advisory LLC increased its holdings in Supernus Pharmaceuticals by 2.2% during the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company's stock valued at $520,000 after buying an additional 309 shares during the last quarter. Summit Investment Advisors Inc. increased its stake in shares of Supernus Pharmaceuticals by 7.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company's stock worth $190,000 after purchasing an additional 369 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Supernus Pharmaceuticals by 6.6% in the fourth quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company's stock worth $275,000 after purchasing an additional 473 shares in the last quarter. HighTower Advisors LLC increased its stake in shares of Supernus Pharmaceuticals by 7.3% in the fourth quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock worth $330,000 after purchasing an additional 624 shares in the last quarter. Finally, Raiffeisen Bank International AG purchased a new stake in shares of Supernus Pharmaceuticals in the fourth quarter worth $25,000.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on SUPN shares. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday. Cantor Fitzgerald raised shares of Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and set a $42.00 price target on the stock in a research note on Wednesday.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN traded up $0.41 during trading on Friday, reaching $35.51. 858,699 shares of the company's stock traded hands, compared to its average volume of 755,351. Supernus Pharmaceuticals, Inc. has a 12-month low of $27.05 and a 12-month high of $40.28. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of 31.99 and a beta of 0.74. The company's 50 day simple moving average is $32.64 and its two-hundred day simple moving average is $33.37.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.